Trends of average and best race times for IRONMAN^® age group triathletes. by Beat Knechtle (5504402)

Subjects:

S2 Data - by Beat Knechtle (5504402)

Subjects:

Number of finishers by sex and men-to-women ratio over the years between 2002 and 2022. by Beat Knechtle (5504402)

Subjects:

Split and overall IRONMAN^® race times histograms for women and men. by Beat Knechtle (5504402)

Subjects:

Men-to-women ratio across age groups. by Beat Knechtle (5504402)

Subjects:

Trend of the sex difference across years in overall race time. by Beat Knechtle (5504402)

Subjects:

Lipid layer thickness distribution in the inferior half of cornea (nm). by Yongwoo Lee (2265172)

Subjects:

Flowchart of overall study protocol. by Yongwoo Lee (2265172)

Subjects:

Changes in symptom scores and signs of dry eye disease and meibomian gland dysfunction after treatment with intensive pulse light and meibomian gland expression (n =  218). by Yongwoo Lee (2265172)

Subjects:

Change in the vertical distribution of the lipid layer thickness after intensive pulse light treatment (IPL; nm) combined with meibomian gland expression (MGX). by Yongwoo Lee (2265172)

Subjects:

Patient demographics. by Yongwoo Lee (2265172)

Subjects:

The catalase enzyme response of <i>A</i>. <i>albopictus</i> larvae decreased (1.5-fold) in response to <i>M</i>. <i>robertsii</i>-derived copper nanoparticles. by Perumal Vivekanandhan (4863484)

Receiver operating characteristic curve for anti-NIE antibodies for <i>S. stercoralis.</i> by Jannet A. Tobon Ramos (20855642)

“…The seroprevalence did not significantly decrease following DA treatment. These results include all individuals sampled, irrespective of whether they took the medications. …”

Between the PCSO-524 group and the placebo group unpaired comparisons of the change between visits of quality of life and respiratory variables scores. by Nattapon Riengvirodkij (11268720)

Subjects:

A flow diagram outlining the number of dogs in each group during the study (visit 1 = day 0, visit 2 = day 35, and visit 3 = day 70). by Nattapon Riengvirodkij (11268720)

Subjects:

Distribution of quality of life and respiratory variables scores of all 3 visits (visit = day 0, visit 2 = day 35, and visit 3 = day 70) of the PCSO-524 group and the placebo group... by Nattapon Riengvirodkij (11268720)

Subjects:

The baseline characteristics of classifications and body condition score of the 2 groups (frequencies) at entry (visit 1, day 0). by Nattapon Riengvirodkij (11268720)

Subjects:

Tricuspid regurgitation pressure gradient of all 17 dogs. by Nattapon Riengvirodkij (11268720)

Subjects:

Tricuspid regurgitation pressure gradient in the PCSO-524 and placebo groups. by Nattapon Riengvirodkij (11268720)

Subjects:

Reducing Dscam1 diversity decreases adult lifespan in a cluster-specific manner, also see S6 and S7 Figs. by Haiyang Dong (4783608)